Lecanemab

Summary

Lecanemab (CHEMBL3833321) is an approved antibody (ATC N06DX04); indicated across 2 conditions including alzheimer disease and dementia.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Antibody
• ATC class: N06DX04
• Indications: 2 conditions
• Clinical trials: 19

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL3833321
Name	Lecanemab
Type	Antibody
Max phase	4
ATC	N06DX04

Also known as: Ban 2401, BAN-2401, BAN2401, Lecanemab, Lecanemab irmb, Lecanemab-irmb, Leqembi, LECANEMAB

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (2 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
Alzheimer disease	4	MONDO:0004975	MONDO:0004975
dementia	4	MONDO:0001627	HP:0000726

Clinical trials

Total trials: 19.

Phase distribution

Phase	Trials
Not specified	6
PHASE3	3
PHASE2	3
PHASE1	3
PHASE2/PHASE3	2
PHASE4	1
EARLY_PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT07604896	PHASE4	RECRUITING	Evaluating the Efficacy and Safety of Lecanemab in Alzheimer’s Disease Through Multi-omics Approachs
NCT01760005	PHASE2/PHASE3	ACTIVE_NOT_RECRUITING	Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer’s Disease Caused by a Genetic Mutation. Master Protocol DIAN-TU-001
NCT04468659	PHASE3	ACTIVE_NOT_RECRUITING	AHEAD 3-45 Study: A Study to Evaluate Efficacy and Safety of Treatment With Lecanemab in Participants With Preclinical Alzheimer’s Disease and Elevated Amyloid and Also in Participants With Early Preclinical Alzheimer’s Disease and Intermediate Amyloid
NCT05269394	PHASE2/PHASE3	ACTIVE_NOT_RECRUITING	Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals With a Type of Early Onset Alzheimer’s Disease Caused by a Genetic Mutation (DIAN-TU)
NCT06384573	PHASE3	ACTIVE_NOT_RECRUITING	DIAN-TU Amyloid Removal Trial (ART) in Dominantly Inherited Alzheimer’s Disease
NCT06530732	PHASE3	RECRUITING	Deep Cervical Lymphatlc-Venous Anastomosis Surgery for the Treatment of Alzheimer’s Disease: A Pilot Study (DIVA Study)
NCT06602258	PHASE2	ACTIVE_NOT_RECRUITING	A Study of E2814 With Concurrent Lecanemab Treatment in Participants With Early Alzheimer’s Disease
NCT07212062	PHASE2	NOT_YET_RECRUITING	The Purpose of This Study is to Evaluate the Safety and Tolerability of X/T+X-EC in Participants With Alzheimer’s Disease Who Are Currently Treated With Lecanemab.
NCT01767311	PHASE2	COMPLETED	A Study to Evaluate Safety, Tolerability, and Efficacy of Lecanemab in Subjects With Early Alzheimer’s Disease
NCT02094729	PHASE1	COMPLETED	A Randomized, Double-blind, Placebo-controlled Study to Assess Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Pharmacodynamic Response of Repeated Intravenous Infusions of BAN2401 in Subjects With Mild Cognitive Impairment Due to Alzheimer’s Disease and Mild Alzheimer’s Disease
NCT05045716	PHASE1	COMPLETED	A Study of Subcutaneous Lecanemab in Healthy Participants
NCT05533801	PHASE1	COMPLETED	A Study to Demonstrate the Bioequivalence of Lecanemab Supplied in Vials and a Single-Use Auto-Injector (AI) in Healthy Participants
NCT05469009	EARLY_PHASE1	ACTIVE_NOT_RECRUITING	Safety and Feasibility of Exablate Blood-Brain Barrier Disruption for Mild Cognitive Impairment or Mild Alzheimer’s Disease Undergoing Standard of Care Monoclonal Antibody (mAb) Therapy
NCT05925621	Not specified	RECRUITING	Cognitive Neurology Unit Clinical Registry
NCT06285448	Not specified	ENROLLING_BY_INVITATION	Feasibility of Lecanemab Registry and Clinical Outcome Measures
NCT06741553	Not specified	RECRUITING	Prospective Cohort Study of Patients With Early Alzheimer’s Disease Treated With Lecanemab
NCT07152418	Not specified	NOT_YET_RECRUITING	Therapeutic Efficacy of Monoclonal Antibody Drugs for Alzheimer’s Disease Based on PET Research
NCT07505095	Not specified	NOT_YET_RECRUITING	Efficacy of Lecanemab at Different Therapeutic Doses for Alzheimer’s Disease (AD) in Real-World Practice
NCT07544953	Not specified	NOT_YET_RECRUITING	Amyloid Monoclonal Antibody Treatment in PD Patients With Coexistent AD Pathology

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).